Emerging drugs for high-grade osteosarcoma

Expert Opinion on Emerging Drugs

Volumn 15, Issue 4, 2010, Pages 615-634

  Hattinger, Claudia Maria ^a   Pasello, Michela ^a   Ferrari, Stefano ^a   Picci, Piero ^a   Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

drug resistance; osteosarcoma; tailored therapy; target specific drugs; therapeutic markers

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 [[3 [4 [5 [2 (3 FLUOROANILINO) 2 OXOETHYL] 1H PYRAZOL 3 YLAMINO] 7 QUINAZOLINYLOXY]PROPYL](ETHYL)AMINO]ETHYL DIHYDROGEN PHOSPHATE; AMG 479; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BROSTALLICIN; CANFOSFAMIDE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CIXUTUMUMAB; CP 751871; CURCUMIN; DANUSERTIB; DASATINIB; DEFEROLIMUS; DEFOROLIMUS; DOXORUBICIN; ENDOSTAR; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; EZATIOSTAT; FIGITUMUMAB; IFOSFAMIDE; IMC A12; METHOTREXATE; MK 0646; MLN 8237; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PAZOPANIB; PEGINTERFERON ALPHA2B; PHOSPHATIDYLETHANOLAMINE; RAPAMYCIN; ROBATUMUMAB; ROSCOVITINE; SARACATINIB; SCH 717454; SLIT; SORAFENIB; TEMSIROLIMUS; TLK 199; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOTRIENT; ZOLEDRONIC ACID;

ADVANCED CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; EVENT FREE SURVIVAL; GENE TARGETING; HUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REVIEW; URINARY TRACT DISEASE;

EID: 78649460883     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.505603     Document Type: Review

References (101)

1. Campanacci M. High grade osteosarcomas. In: Campanacci M, editor, Bone and soft tissue tumors. 2nd edition. Springer-Verlag, New York; 1999. p. 463-515
2. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-41
3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075-85
4. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2010;152:3-13 • Important updated epidemiologic information about osteosarcoma.
5. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31
6. Lamourex F, Trichet V, Chipoy C, et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007;7:169-81
7. Gaffney R, Unni KK, Sim FH, et al. Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol 2006;37:1009-14 •• A very interesting and historical report about the clinical outcome of high-grade osteosarcoma patients treated without chemotherapy.
8. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30 • An interesting and historical report on the first use of chemotherapy for the treatment of high-grade osteosarcoma.
9. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-21
10. Salzer-Kuntschik M, Brand G, Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 1983;4:135-41
11. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-61
12. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19:341-6
13. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 2009;45:2367-75
14. Stiller CA, Passmore SJ, Kroll ME, et al. Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980-1994. Br J Cancer 2006;94:22-9
15. Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-75
16. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27
17. Biason P, Toffoli G. Sarcomas and pharmacogenetics. Pharmacogenomics 2005;6:585-601
18. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5
19. Chan HS, Grogan TM, Haddad G, et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997;89:1706-15
20. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 2003;98:581-9
21. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21:536-42
22. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8
23. Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007;25:2057-62
24. Serra M, Picci P, Ferrari S, et al. Prognostic value of P-glycoprotein in high-grade osteosarcoma. J Clin Oncol 2007;25:4858-60
25. Schwartz CL, Gorlick R, Teot L, et al. Prognostic value of P-glycoprotein in high-grade osteosarcoma. J Clin Oncol 2007;25:4860; author reply
26. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5:621-7
27. Ifergan I, Melter I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma. Cancer 2003;98:1958-66
28. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004;15:151-60
29. Scionti I, Michelacci F, Pasello M, et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 2008;19:1500-8
30. Hattinger CM, Reverter-Branchat G, Remondini D, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003;82:483-93
31. Hattinger CM, Stoico G, Michelacci F, et al. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009;48:289-309
32. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79
33. Pasello M, Michelacci F, Scionti I, et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 2008;68:6661-8
34. Meyers PA, Schwartz CL, Krailo MD. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-8
35. Scotlandi K, Picci P, Kovar H. Targeted therapies in bone sarcomas. Curr Cancer Drug Targets 2009;9:843-53
36. Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 1999;80:581-8
37. Messerschmitt PJ, Rettew AN, Brookover RE, et al. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008;466:2168-75 •• A very interesting report about the preclinical efficacy of specific tyrosine kinase inhibitors in human osteosarcoma cell lines.
38. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009;115:5243-50
39. Yamaguchi U, Honda K, Satow R, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009;100:2268-74
40. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009;14:83-91 •• Recent review on the biologic role of IGF-1R in pediatric malignancies and its potential as therapeutic target.
41. Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 2009;69:2443-52
42. Hughes DP. Novel agents in development for pediatric sarcomas. Curr Opin Oncol 2009;21:332-7
43. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1198-206 • Nice example of the work performed by the Pediatric Preclinical Testing Program. (Pubitemid 351555544)
44. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751, 871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
45. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-20
46. Sabatino MA, Colombo T, Geroni C, et al. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8
47. Pezzola S, Antonini G, Geroni C, et al. Role of glutathione transferases in the mechanism of brostallicin activation. Biochemistry 2010;49:226-35
48. Hamilton D, Batist G. TLK-199 (Telik). IDrugs 2005;8:662-9
49. Morgan AS, Ciaccio PJ, Tew KD, et al. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 1996;37:363-70
50. Sequist LV, Fidias PM, Temel JS, et al. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1389-96
51. Vergote I, Finkler N, Del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or-resistant ovarian cancer. Eur J Cancer 2009;45:2324-32
52. Cai D, Latham VM, Zhang X, et al. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006;66:9270-80
53. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20 • Interesting overview on the rationale of clinical application of protein kinase inhibitors and modulators for treatment of human cancers.
54. Crescenzi E, Palumbo G, Brady HJ. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res 2005;11:8158-71
55. Lambert LA, Qiao N, Hunt KK, et al. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 2008;68:7966-74
56. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37
57. Saeki T, Ouchi M, Ouchi T. Physiological and oncogenic aurora-a pathway. Int J Biol Sci 2009;5:758-62
58. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15:6694-701
59. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27:5094-101
60. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;54:921-6
61. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008;7:3461-9 •• Recent review explaining very well the biology of osteoclasts and the rational for osteoclast-targeted therapy to cure osteosarcoma.
62. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-8
63. Hingorani P, Zhang W, Gorlick R, et al. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009;15:3416-22
64. Zhou Q, Deng Z, Zhu Y, et al. mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2009. [Epub ahead of print]
65. Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-11
66. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805
67. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2010;16:530-40
68. Strimpakos AS, Karapanagiotou EM, Saif MW, et al. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35:148-59 • An interesting review of the role of mTOR in cancer and its inhibition.
69. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007;25:4806-12
70. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP2 3573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7
71. El-Houseini ME, Abdel-Azim SA, El-Desouky GI, et al. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Natl Canc Inst 2004;16:57-61
72. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7 • An interesting report on the clinical impact of vascular endothelial growth factor in osteosarcoma.
73. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006;19:738-45
74. Charity RM, Foukas AF, Deshmukh NS, et al. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 2006;448:193-8
75. Maris JM, Courtright J, Houghton PJ, et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:581-7 (Pubitemid 351155829)
76. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009;8:118-35 • An important report about the preclinical effectiveness of sorafenib in osteosarcoma.
77. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008;10:315-27
78. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005;65:1748-54
79. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008;17:1703-15
80. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80
81. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007;6:3263-70
82. Labrinidis A, Hay S, Liapis V, et al. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15:3451-61
83. Labrinidis A, Hay S, Liapis V, et al. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int J Cancer 2009. [Epub ahead of print]
84. Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86
85. Benassi MS, Chiechi A, Ponticelli F, et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 2007;250:194-205
86. Ory B, Moriceau G, Trichet V, et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008;12:928-41
87. Gatti L, Beretta GL, Cossa G, et al. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009;9:1102-12
88. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775:237-62
89. Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
90. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, et al. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res 2006;29:866-73 (Pubitemid 44808452)
91. Chearwae W, Shukla S, Limtrakul P, et al. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 bythe cancer chemopreventive agent curcumin. Mol Cancer Ther 2006;5:1995-2006
92. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006;103:1888-93
93. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8
94. Muller CR, Paulsen EB, Noordhuis P, et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199-205
95. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 2007;5:1133-45
96. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009;9:1035-49
97. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115:5339-48
98. Manara MC, Serra M, Benini S, et al. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 2004;24:365-72
99. Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha is the only adjuvant treatment in high grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005;44:475-80
100. Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010;54:350-4 • An interesting review of the role of interferons for the treatment of high-grade OS.
101. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Exp Rev Anticancer Ther 2009;9:511-23